Current status and future direction in the management of malignant melanoma

被引:48
作者
Gladfelter, Patrick [1 ]
Darwish, Noureldien H. E. [1 ,2 ]
Mousa, Shaker A. [1 ]
机构
[1] Albany Coll Pharm & Hlth Sci, Pharmaceut Res Inst, Rensselaer, NY USA
[2] Mansoura Univ, Dept Clin Pathol, Fac Med, Mansoura, Egypt
关键词
BRAF; CTLA-4; MEK inhibitor; melanoma; nanoparticle; programmed cell death 1 receptor; photodynamic therapy; PHASE-II TRIAL; METASTATIC MELANOMA; OPEN-LABEL; PHOTODYNAMIC THERAPY; FEEDBACK INHIBITION; CUTANEOUS MELANOMA; IMPROVED SURVIVAL; TARGETED THERAPY; ADJUVANT THERAPY; BRAF-MUTANT;
D O I
10.1097/CMR.0000000000000379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The incidence of malignant melanoma is increasing rapidly on a global scale. Although some types of melanoma, for example primary cutaneous melanoma, can be managed by surgery, metastatic melanoma cannot and it has a high mortality rate. Both oncogene and immune-targeted strategies have shown marked efficacy in some patients, but their effect on overall survival is still variable. Therefore, newer therapeutic approaches are needed. Fortunately, new advances in molecular medicine have led to an understanding of an individual patient's cancer at the genomic level. This information is now being used in all stages of cancer treatment including diagnosis, treatment selection, and treatment monitoring. This new strategy of personalized medicine may lead to marked shifts in immunotherapeutic treatment approaches such as individualized cancer vaccines and adoptive transfer of genetically modified T cells. This review provides an overview of recent approaches in cancer research and expected impact on the future of treatment for metastatic melanoma. Copyright (C) 2017 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:403 / 410
页数:8
相关论文
共 87 条
[1]   Immunotherapies and novel combinations: the focus of advances in the treatment of melanoma [J].
Ascierto, Paolo A. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2015, 64 (03) :271-274
[2]   Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma [J].
Ascierto, Paolo A. ;
Minor, David ;
Ribas, Antoni ;
Lebbe, Celeste ;
O'Hagan, Anne ;
Arya, Niki ;
Guckert, Mary ;
Schadendorf, Dirk ;
Kefford, Richard F. ;
Grob, Jean-Jacques ;
Hamid, Omid ;
Amaravadi, Ravi ;
Simeone, Ester ;
Wilhelm, Tabea ;
Kim, Kevin B. ;
Long, Georgina V. ;
Martin, Anne-Marie ;
Mazumdar, Jolly ;
Goodman, Vicki L. ;
Trefzer, Uwe .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (26) :3205-+
[3]   MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study [J].
Ascierto, Paolo A. ;
Schadendorf, Dirk ;
Berking, Carola ;
Agarwala, Sanjiv S. ;
van Herpen, Carla M. L. ;
Queirolo, Paola ;
Blank, Christian U. ;
Hauschild, Axel ;
Beck, J. Thaddeus ;
St-Pierre, Annie ;
Niazi, Faiz ;
Wandel, Simon ;
Peters, Malte ;
Zubel, Angela ;
Dummer, Reinhard .
LANCET ONCOLOGY, 2013, 14 (03) :249-256
[4]   Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma:: A phase III study [J].
Avril, MF ;
Aamdal, S ;
Grob, JJ ;
Hauschild, A ;
Mohr, P ;
Bonerandi, JJ ;
Weichenthal, M ;
Neuber, K ;
Bieber, T ;
Gilde, K ;
Porta, VG ;
Fra, J ;
Bonneterre, J ;
Saïag, P ;
Kamanabrou, D ;
Pehamberger, H ;
Sufliarsky, J ;
Larriba, JLG ;
Scherrer, A ;
Menu, Y .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1118-1125
[5]   Final Version of 2009 AJCC Melanoma Staging and Classification [J].
Balch, Charles M. ;
Gershenwald, Jeffrey E. ;
Soong, Seng-jaw ;
Thompson, John F. ;
Atkins, Michael B. ;
Byrd, David R. ;
Buzaid, Antonio C. ;
Cochran, Alistair J. ;
Coit, Daniel G. ;
Ding, Shouluan ;
Eggermont, Alexander M. ;
Flaherty, Keith T. ;
Gimotty, Phyllis A. ;
Kirkwood, John M. ;
McMasters, Kelly M. ;
Mihm, Martin C., Jr. ;
Morton, Donald L. ;
Ross, Merrick I. ;
Sober, Arthur J. ;
Sondak, Vernon K. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (36) :6199-6206
[6]   CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].
Buchbinder, Elizabeth I. ;
Desai, Anupam .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106
[7]   Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study) [J].
Busse, Antonia ;
Rapion, Jerome ;
Fusi, Alberto ;
Suciu, Stefan ;
Nonnenmacher, Anika ;
Santinami, Mario ;
Kruit, Wim H. J. ;
Testori, Alessandro ;
Punt, Cornelis J. A. ;
Dalgleish, Angus G. ;
Spatz, Alan ;
Eggermont, Alexander M. M. ;
Keilholz, Ulrich .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (07) :1223-1233
[8]   Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].
Chapman, Paul B. ;
Hauschild, Axel ;
Robert, Caroline ;
Haanen, John B. ;
Ascierto, Paolo ;
Larkin, James ;
Dummer, Reinhard ;
Garbe, Claus ;
Testori, Alessandro ;
Maio, Michele ;
Hogg, David ;
Lorigan, Paul ;
Lebbe, Celeste ;
Jouary, Thomas ;
Schadendorf, Dirk ;
Ribas, Antoni ;
O'Day, Steven J. ;
Sosman, Jeffrey A. ;
Kirkwood, John M. ;
Eggermont, Alexander M. M. ;
Dreno, Brigitte ;
Nolop, Keith ;
Li, Jiang ;
Nelson, Betty ;
Hou, Jeannie ;
Lee, Richard J. ;
Flaherty, Keith T. ;
McArthur, Grant A. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516
[9]   Phase III multicenter randomized trial of the dartmouth regimen versus dacarbazine in patients with metastatic melanoma [J].
Chapman, PB ;
Einhorn, LH ;
Meyers, ML ;
Saxman, S ;
Destro, AN ;
Panageas, KS ;
Begg, CB ;
Agarwala, SS ;
Schuchter, LM ;
Ernstoff, MS ;
Houghton, AN ;
Kirkwood, JM .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2745-2751
[10]   Involvement of ABC transporters in melanogenesis and the development of multidrug resistance of melanoma [J].
Chen, Kevin G. ;
Valencia, Julio C. ;
Gillet, Jean-Pierre ;
Hearing, Vincent J. ;
Gottesman, Michael M. .
PIGMENT CELL & MELANOMA RESEARCH, 2009, 22 (06) :740-749